MSAC stakeholder meeting for CAR-T cell therapy for relapsed or refractory Diffuse Large B Cell Lymphoma, Primary Mediastinal B-cell Lymphoma and Follicular LymphomaThe Medical Services Advisory Committee (MSAC) will hold a stakeholder meeting on 12 November 2019 on CAR-T cell therapy for relapsed or refractory Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), and Follicular Lymphoma (FL).
The purpose of the meeting is to allow MSAC to seek advice on patient eligibility for treatment and other aspects of patient management, in light of the recent MSAC consideration of Kymriah® (tisagenlecleucel, sponsored by Novartis Australia) and the future MSAC consideration of Yescarta® (axicabtagene ciloleucel, sponsored by Gilead Sciences).
MSAC has invited treating clinicians, consumers, and representatives of Novartis and Gilead and the Commonwealth and State/Territory health departments to attend the meeting.
Description of Medical ServiceTisagenlecleucel is an autologous, murine anti-CD19 Chimeric Antigen Receptor T cell (CAR-T) therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.
Description of Medical ConditionDiffuse Large B-Cell Lymphoma (DLBCL) is an aggressive and common subtype of Non-Hodgkin Lymphoma (NHL).
Reason for ApplicationRe-submission
Medical Service TypeHybrid health technology
Previous Application Number1519
Consultation SurveyFeedback and comments are welcome at any stage during the MSAC process. Please provide comments on Application 1519.1 via a maximum of two A4 pages to HTA@health.gov.au (making sure that you type the application number at the start of your comments and in the subject heading of your email).
Public Summary DocumentPublic Summary Document (PDF 1143 KB)
Public Summary Document (Word 213 KB)